Cited by 13Developmental Biology and Gene RegulationTGF-β signaling in diseasesTelomeres, Telomerase, and Senescence

PDCD4 is a CSL associated protein with a transcription repressive function in cancer associated fibroblast activation

Open access
Jo, Seung-Hee, Kim, Dong Eun, Clocchiatti, Andrea, Dotto, G. Paolo·2016·Oncotarget

Abstract

// Seung-Hee Jo 1,2 , Dong Eun Kim 3 , Andrea Clocchiatti 1,2 and G. Paolo Dotto 1,3 1 Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, MA, USA 2 Department of Dermatology, Harvard Medical School, Boston, MA, USA 3 Department of Biochemistry, University of Lausanne, Epalinges, CH, Switzerland Correspondence to: G. Paolo Dotto, email: // Keywords : PDCD4, Notch/CSL signaling, transcription repression, squamous cancer, CAFs Received : May 12, 2016 Accepted : July 22, 2016 Published : August 11, 2016 Abstract The Notch/CSL pathway plays an important role in skin homeostasis and carcinogenesis. CSL, the key effector of canonical Notch signaling endowed with an intrinsic transcription repressive function, suppresses stromal fibroblast senescence and Cancer Associated Fibroblast (CAF) activation through direct down-modulation of key effector genes. Interacting proteins that participate with CSL in this context are as yet to be identified. We report here that Programmed Cell Death 4 (PDCD4), a nuclear/cytoplasmic shuttling protein with multiple functions, associates with CSL and plays a similar role in suppressing dermal fibroblast senescence and CAF activation. Like CSL, PDCD4 is down-regulated in stromal fibroblasts of premalignant skin actinic keratosis (AKs) lesions and squamous cell carcinoma (SCC). While devoid of intrinsic DNA binding capability, PDCD4 is present at CSL binding sites of CAF marker genes as well as canonical Notch/CSL targets and suppresses expression of these genes in a fibroblast-specific manner. Thus, we propose that PDCD4 is part of the CSL repressive complex involved in negative control of stromal fibroblasts conversion into CAFs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.11227

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jo, S.-H., Kim, D. E., Clocchiatti, A., & Dotto, G. P.
Affiliations
  • Harvard University (US)
  • University of Lausanne (CH)
  • Massachusetts General Hospital (US)
Corresponding author
Dotto, G. Paolo
Venue
Oncotarget
Published
2016-08-11
Volume
7
Issue
37
Pages
58717-58727
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2509012192
Cited by
13
References
31
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 1
FWCI
0.87
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Oncotarget (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (acceptedVersion, other-oa)
  • IRIS (submittedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (156191, 310030)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR039190, R01AR064786)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
Keywords
PDCD4, CSL, Notch signaling, cancer-associated fibroblasts, fibroblast senescence, transcriptional repression, squamous cell carcinoma, actinic keratosis, dermal fibroblasts, protein-protein interaction, skin carcinogenesis
MeSH terms
Cancer-Associated Fibroblasts, Animals, Carcinoma, Squamous Cell, HeLa Cells, Humans, Protein Binding, Skin Neoplasms, Transcription, Genetic, Signal Transduction, Down-Regulation, Mice, SCID, RNA-Binding Proteins, Cellular Senescence, Xenograft Model Antitumor Assays, RNA, Small Interfering, Cell Line, Tumor, Apoptosis Regulatory Proteins, Mice, Immunoglobulin J Recombination Signal Sequence-Binding Protein, Keratosis, Actinic, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review